MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology, Inc. has priced its initial public offering of 2,000,000 shares at $5.00 each, expecting gross proceeds of $10,000,000. The shares will trade under the ticker symbol MAIA starting July 28, 2022, with the offering closing on August 1, 2022, pending customary conditions. The proceeds will fund Phase 2 trials for the product candidate THIO, pre-clinical development of new compounds, and general corporate purposes. ThinkEquity is managing the offering.